The case for & against
Bull & Bear analysis
Schrödinger, Inc. (NASDAQ: SDGR) is a leading biotechnology company specializing in computational drug discovery and molecular design. It leverages advanced physics-based simulations and artificial intelligence (AI) technologies to enhance the drug discovery process, catering primarily to the pharmaceutical industry. With a growing emphasis on transforming traditional biopharmaceutical research, Schrödinger is positioned well amid the increasing regulatory pressures to reduce animal testing, as it offers predictive models for drug development while managing a diverse revenue stream from both software solutions and collaborative drug discovery partnerships.
Bull says
- ↑Q1 revenue of $58.6M, up 12% YoY; ACV reached $28.4M
- ↑Hosted licensing rose to 34% of software revenue from 24%
- ↑Upcoming Bunsen AI platform aims to automate and scale workflows
- ↑Cash and marketable securities at $406M provide runway for growth
- ↑Predictive toxicology initiative aligns with regulatory push to reduce animal testing
- ↑Strong liquidity and institutional interest support strategic flexibility
Bear says
- ↓Q1 net loss of $60M persists, pressuring profitability turnaround
- ↓Operating expenses increased to $78M, straining future cash flows
- ↓Software gross margin declined to 69% from 80% year-ago
- ↓Dependence on collaborations may cause revenue volatility if deals slow
- ↓High stock volatility and regulatory uncertainty deter risk-averse investors
- ↓Negative earnings yield and weak profitability factors hamper returns
Investment themes with SDGR
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- Our therapeutics business continues to create significant value, most recently highlighted by Lilly's planned acquisition of Ajax Therapeutics for $2.3 billion.
- The success of these companies and multi-billion dollar exits establishes unquestionable validation of the impact of computational physics-based design and our biotech and pharma collaboration business model.
- The data presented demonstrate that SGR3515 was generally well tolerated on an intermittent dosing schedule of 3 days on and 11 days off. Importantly, the initial clinical biomarker data validated our hypothesis that dual inhibition can overcome compensatory resistance mechanisms.
Bear points
- The decline is driven by completion of the initial funding by the Gates Foundation in support of our predictive toxicology initiative.